Shares of Johnson & Johnson are in focus on Tuesday after the company posted second quarter results which were better than what Wall Street was expecting. Johnson & Johnson says sales around the world were strong. Excluding one time charges, J&J earned $1.66 a share, that's more than 10 cents better than expectations. Revenue for the quarter was $19.5 billion, slightly better than expectations and a 9% increase compared to the same period a year ago. The highlight of the quarter were sales in the U.S. which jumped almost 15%. International sales rose more than 4%. The new star product was the hepatitis C treatment Olysio. Sales for the drug reached $831 million globally in the second quarter, more than doubled its sales in the first quarter of this year. TheStreet's Julia Sun reports from New York.
Stock quotes in this video: